SuperGen Inc.
4140 Dublin Boulevard
Suite 200
Dublin,
CA 94568
United States - Map
Phone: 925-560-0100
Fax: 925-560-0101
Web Site: http://www.supergen.com
| SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. The company licensed its new drug application approved product, Dacogen for the treatment of patients with myelodysplastic syndromes. It primarily focuses on developing MP-470, a DNA repair suppressor; SGI-1776, a PIM kinase inhibitor; MP-529, an Aurora kinase inhibitor; SGI-110, a DNMT1 inhibitor; and SGI-1252, a JAK2 inhibitor. SuperGen also has an approved product, Mitozytrex for the treatment of solid tumors. In addition, the company is developing Orathecin, a Phase III clinical trial product for the treatment of solid tumors; Partaject busulfan, a Phase I/II clinical trial product for neoplastic meningitis/bone marrow transplant; Partaject Orathecin, a non-clinical stage product for the treatment of solid tumors; and CZ 112, a Phase I clinical trial product for the treatment of solid tumors. It is also developing Cremophor-free paclitaxel, a non-clinical stage product for the treatment of solid tumors; Avicine, a therapeutic vaccine for the treatment of cancer, which is in Phase II trial; VEGF, a non-clinical stage product for the treatment of anti-angiogenesis; PZG, a Phase II clinical trial product for the treatment of type II diabetes; and AM454, a phosphocholine derivative, which is in non-clinical stage for obesity/diabetes. The company sells its products to clinics, hospitals, hospital buying groups, drug distributors, and wholesalers in the United States and Europe. It has a collaboration agreement with GlaxoSmithKline Inc. to discover and develop cancer therapeutics based on epigenetic targets. SuperGen was founded in 1991 and is based in Dublin, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. James Manuso Ph.D., 60
Chairman, Chief Exec. Officer and Pres |
N/A
| N/A | Mr. Michael Molkentin CPA, 54
Chief Financial Officer, Principal Accounting Officer and Corp. Sec. |
N/A
| N/A | Dr. Michael D. Young M.D., Ph.D., MBA, 69
Interim Chief Medical Advisor, Director, Member of Governance & Nominating Committee and Member of Pharmaceutical Sub - Committee |
$
32.00K | N/A | Dr. David J. Bearss Ph.D., 40
Biology Consultant and Member of Scientific Advisory Board |
$
281.00K | N/A | Mr. Michael McCullar Ph.D., MBA,
Head of Discovery Operations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 
0.01 (0.38%) 
Profile
